Metastatic Non-Small Cell Lung Cancer (NSCLC)

Oncology·MeSH: Carcinoma, Non-Small-Cell Lung

Prevalence

75.0 / 100K

Incidence

47.0 / 100K/yr

20 drugs in development·11 companies·1 clinical trial

Drug Pipeline by Phase

Approved(5)

Phase 3(9)

Drug	Company
AZD2936	ASTRAZENECA PLC (AZN)
AZD8205 and AZD5305 and AZD2936	ASTRAZENECA PLC (AZN)
eftilagimod alfa	Immutep Limited (IMMP)
eftilagimod alfa	IMMUTEP Ltd (PRRUF)
Eftilagimod Alfa	Immutep Limited (IMMP)
MEDI5752	ASTRAZENECA PLC (AZN)
Oleclumab	ASTRAZENECA PLC (AZN)
tak-788	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-788	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(1)

Drug	Company
cylembio	IO Biotech, Inc. (IOBT)

Phase 1(5)

BioSniper tracks 20 drugs in development for Metastatic Non-Small Cell Lung Cancer (NSCLC) across 11 companies.

There are 1 clinical trial targeting Metastatic Non-Small Cell Lung Cancer (NSCLC) tracked by BioSniper.

The estimated prevalence of Metastatic Non-Small Cell Lung Cancer (NSCLC) is approximately 75.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.